Search

You searched for "immunotherapy"

200 results found

Prostate cancer nurse specialist shortage: a view from the coal face

5 November 2019 | | Urologic Oncology
Prostate Cancer UK recently reported that there is an impending crisis for men with prostate cancer, simply because the number of nurse specialists available is insufficient for their needs [1]. Background As has been widely reported, the incidence of prostate...

An algorithm for the management of haemorrhagic cystitis

1 September 2015 | | Endourology and Stones, Functional Urology, Urologic Oncology
Haemorrhagic cystitis (HC) can be one of the most difficult conditions to treat in urological practice. It is characterised by intractable bleeding from the bladder and may be acute or chronic. The most frequently reported causal factors are radiotherapy (RT)...

Demanding cases or nightmares in uro-oncology? Jan/Feb 2023

6 January 2023 | | Urologic Oncology
Radical surgical treatment of prostate cancer has become minimally invasive owing to robotic assisted laparoscopic technology [1]. Patients who undergo robotic assisted radical prostatectomy (RARP) often have lower risk of morbidity compared to an open approach. However, patients with a...

Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer

1 July 2017 | | Urologic Oncology
Abiraterone acetate, the prodrug of abiraterone, blocks endogenous androgen synthesis by inhibiting cytochrome p-450c17, a critical enzyme in androgen biosynthesis. Its active D4A metabolite also has anti-tumour effects through possibly multiple mechanisms. 3-5% of men diagnosed with prostate cancer in...

The process of medical innovation – evolving trends and future perspectives

5 May 2021 | | Technological Developments
In 2018 the United Kingdom Government spending on healthcare totalled almost £166 billion. Of this approximately 65% was attributed to providing curative or rehabilitation therapy, with health-related long-term care and provision of goods accounting for 25%. The remaining was accredited...

Prostate cancer survivorship: a new path for uro-oncology

1 July 2015 | | Urologic Oncology
Over two million people in England have a diagnosis of cancer [1]. Of this figure, over 250,000 have been diagnosed with prostate cancer [2]. However, during the next decade, a rapid increase in the number of new cancer diagnoses, as...

Inguino-scrotal sarcomas

1 May 2019 | | Andrology, Urologic Oncology, Uroradiology
A sarcoma is a malignant tumour that originates from mesenchymal cells such as adipose tissue, bone, cartilage and smooth muscle. Although these tumours histologically do not originate from the urogenital tract, urologists are often involved in their diagnosis and management...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

1 May 2017 | | Urologic Oncology
Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

Covid-19, cancer, and other calamities

6 April 2020 | | COVID-19 - Urology News
The coronavirus (Covid-19) pandemic is upon us. The government and NHS are going full-steam ahead with their preparations for the onslaught, freeing up operating theatres, intensive care units, and even private hospital beds and staff, to accommodate the expected influx...

Feeling like a fraud — imposter syndrome: what it is and what to do about it

17 April 2024 |
Have you ever been plagued by feelings of incompetence despite evidence to the contrary, then this article is for you. Dr Dunay Schmulian provides insight into imposter syndrome and what to do about it. Excerpt 1 Consultant:That was excellent, and...

ICS updates on continence care: making sense of detrusor underactivity and the underactive bladder

1 July 2016 | | Functional Urology
Countless epidemiological studies have established the frequent occurrence of lower urinary tract symptoms (LUTS) and the significant burden these symptoms incur. For the most part of the past three decades, there has been an overwhelming focus on detrusor overactivity (DO)...

Focal therapy trials

6 November 2020 | | Urologic Oncology
Men with localised prostate cancer have traditionally required whole gland treatment involving radical prostatectomy or radical radiation treatment, independent of disease location and size. Increasing evidence supports the use of active treatment only in those men diagnosed with prostate cancer...